Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nanobiotix
  6. News
  7. Summary
    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nanobiotix's Cancer Drug Shows Potential As Combination Therapy In Preclinical Study

11/10/2021 | 12:33am EST


ę MT Newswires 2021
All news about NANOBIOTIX
01/10NANOBIOTIX : Provides Corporate Update and Highlights Key 2022 Milestone Targets - Form 6-..
PU
01/10NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
BU
01/05Nanobiotix Enrolls First Patient In Late-Stage Trial For Head, Neck Cancer Treatment
MT
01/05Nanobiotix Enrolls First Patient in Phase 3 Study of Head, Neck Cancer Treatment
MT
01/05NANOBIOTIX : Announces First Patient Enrolled in NANORAY-312 Global Phase III Registration..
PU
01/05NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registratio..
BU
01/05Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Regist..
CI
01/04Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 202..
BU
2021NANOBIOTIX : Monthly statement on outstanding equity shares and voting rights
CO
2021NANOBIOTIX : to Present at the 4th Annual Evercore ISI HealthCONx Conference - Form 6-K
PU
More news
Analyst Recommendations on NANOBIOTIX
More recommendations
Financials
Sales 2021 2,30 M 2,63 M 2,63 M
Net income 2021 -68,1 M -77,7 M -77,7 M
Net cash 2021 74,1 M 84,6 M 84,6 M
P/E ratio 2021 -5,24x
Yield 2021 -
Capitalization 276 M 316 M 315 M
EV / Sales 2021 87,9x
EV / Sales 2022 112x
Nbr of Employees 98
Free-Float 94,5%
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | NANO | FR0011341205 | MarketScreener
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,94 €
Average target price 25,55 €
Spread / Average Target 222%
EPS Revisions
Managers and Directors
Laurent LÚvy Chairman-Executive Board & Chief Executive Officer
Bart van Rhijn Chief Financial Officer
Gary M. Phillips Chairman-Supervisory Board
Margaret Galluzzi Vice President-Global & Head-Clinical Operations
Alain Dostie Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NANOBIOTIX8.62%316
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684